Lifeward (NASDAQ:LFWD – Get Free Report) is expected to announce its Q1 2026 results before the market opens on Friday, May 15th. Analysts expect the company to announce earnings of ($1.18) per share and revenue of $5.7750 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.
Lifeward (NASDAQ:LFWD – Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($3.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($3.53). The firm had revenue of $5.08 million during the quarter, compared to the consensus estimate of $7.87 million. Lifeward had a negative net margin of 90.38% and a negative return on equity of 145.55%. On average, analysts expect Lifeward to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Lifeward Stock Performance
Shares of LFWD opened at $6.48 on Wednesday. The firm has a market capitalization of $9.91 million, a price-to-earnings ratio of -0.35 and a beta of 0.32. The business’s fifty day moving average price is $6.75 and its two-hundred day moving average price is $7.08. Lifeward has a 52 week low of $4.14 and a 52 week high of $17.76.
Institutional Trading of Lifeward
Analyst Upgrades and Downgrades
A number of research analysts have commented on LFWD shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lifeward in a research report on Tuesday, April 21st. HC Wainwright increased their price objective on Lifeward to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lifeward has an average rating of “Hold” and an average target price of $10.00.
Read Our Latest Stock Analysis on Lifeward
Lifeward Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Featured Articles
- Five stocks we like better than Lifeward
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.
